Invivo Capital Partners

What Invivo Capital Partners does

Invivo Capital Partners (legal entity: Invivo Partners S.G.E.I.C. S.A.) is a Barcelona-based venture capital firm founded in 2012, specializing in early-stage investments in life sciences and AI-driven deeptech companies across Europe, with particular focus on Spanish opportunities. The firm manages four fund vehicles: Healthequity (healthcare VC founded 2012), Invivo Ventures (€60M final closing, March 2019, investment period completed 2024), Invivo Ventures III (€100M target, registered with the CNMV November 2023), and Invivo Ventures AI (€100M target, first closing expected H1 2026, the first local Spanish fund dedicated exclusively to AI-driven science). Assets under management exceed €150M, sourced from institutional LPs including the European Investment Fund, ICO, ICF, IVF, and Barcelona City Council alongside majority private investors.

The firm invests at pre-seed (company creation), seed, and Series A stages in preclinical-stage biotechnology companies developing advanced therapies, synthetic biology, RNA, gene therapy, cell therapy, immunotherapy, and gene editing modalities, with initial tickets of €2-4M and follow-on capacity up to €10M per company. Portfolio comprises 17 companies with 4 successful exits to date (Sanifit acquired by Vifor Pharma in 2021, Versantis acquired by Genfit in 2022). The firm has built AIA, a proprietary AI model fine-tuned to its investment logic for deal analysis, competitor landscaping, and scientific talent mapping, and maintains a Scientific Advisory Board including the CRG Director, Novartis BD&L, Alnylam, and MIT/Senti Bio leadership. Revenue is generated through management fees on AUM and carried interest from portfolio exits, with the firm co-investing alongside top-tier international VCs such as Sofinnova Partners, Takeda Ventures, Advent France Biotechnology, and Taiho Ventures.

Name

Invivo Capital Partners

Legal name

Invivo Partners S.G.E.I.C. S.A.

Website

https://invivo.partners

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Invivo Capital Partners is a Barcelona-based venture capital firm managing over €150M across multiple funds, investing €2-4M at seed and Series A in early-stage European life sciences and AI-driven deeptech companies, with 17 portfolio companies and 4 exits.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239), Other Financial Vehicles (525990)

SIC

Investment Advice (6282), Investors, Nec (6799)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industries

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD), Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

Keywords

• Venture capital investing
• Life sciences funding
• Biotech early-stage
• Healthcare venture capital
• AI-driven deeptech investments

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Fund Management: VC firm generates revenue through management fees on assets under management and carried interest (performance fees) from successful portfolio company exits. Manages multiple funds including Healthequity, Invivo Ventures (60M€ final closing), Invivo Ventures III (100M€ target), and Invivo Ventures AI (100M€ target).

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Invivo Capital Partners is a Barcelona-based venture capital firm that manages multiple dedicated life sciences and AI-driven deeptech funds (Invivo Ventures, Invivo Ventures III, Invivo Ventures AI, and Healthequity). It invests 2-4 million euros initially (up to 10 million euros in follow-on) into pre-seed, seed, and preclinical-stage European biotech and AI-driven science companies developing advanced therapies, synthetic biology, RNA, gene and cell therapies, and AI-enabled healthcare solutions. The firm also offers proprietary AI-powered deal screening and due diligence through its AIA platform.

Product overview

Invivo Capital Partners is a venture capital firm managing multiple investment funds focused on early-stage life sciences and AI-driven deeptech companies. The firm operates four main products: (1) Invivo Ventures - the original €60M fund launched in 2019; (2) Invivo Ventures III - a €100M fund launched in 2023 focused on advanced therapies, synthetic biology, and AI; (3) Invivo Ventures AI - an upcoming €100M fund focused exclusively on AI-driven science companies; and (4) AIA - a proprietary AI model that mirrors the firm's investment logic for analyzing deals, building competitive landscapes, and producing research reports. Healthequity is also part of the portfolio, a healthcare-focused VC fund founded in 2012.

Differentiator

Problem solved

Functional benefit

Brands

• Invivo Ventures AI: A €100M vertical fund dedicated to accelerating innovation at the intersection of artificial intelligence (AI) and science, targeting early-stage companies applying AI to advance biotechnology and other science-driven domains.
• Invivo Ventures III
• Invivo Ventures FCR
• Healthequity

Products and services

• Invivo Ventures
• Invivo Ventures III
• Invivo Ventures AI
• Healthequity

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature1 record

Partnerships

One partnership is on record.

• Barcelona Supercomputing Center (BSC)coreStrategic or Co-development PartnerKey strategic partner for Invivo Ventures AI fund focused on AI-driven science. Pep Martorell, newly appointed Partner, previously Associate Director at BSC.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Ysios Capital: Spanish early-stage life sciences VC firm. Directly comparable to Invivo in geography (Spain/Europe), stage (seed/Series A) and sector focus (biotech, advanced therapies).
• Kurma Partners: Paris-based early-stage healthcare VC. Co-invested with Invivo in Corteria Pharmaceuticals; closely comparable in stage focus, therapeutic areas (rare disease, cardiology) and European geography.
• Advent France Biotechnology: French early-stage biotech VC. Repeat co-investor with Invivo in Integra Therapeutics and ARTHEx Biotech; comparable in stage, sector and European footprint.
• Columbus Venture Partners: Spanish biotech-focused VC manager. Co-invested with Invivo in ARTHEx Biotech and Integra Therapeutics; directly comparable in Spanish/European early-stage life sciences focus.
• Inveready: Spanish alternative asset manager with biotech and deeptech strategies. Comparable as a domestic Spanish VC that has also invested in the Spanish life sciences ecosystem.
• V-Bio Ventures: Belgian early-stage biotech VC. Comparable in stage and European footprint; co-invested alongside Invivo in Corteria Pharmaceuticals.
• Alta Life Sciences: Spanish early-stage life sciences investment firm. Directly comparable in geography (Spain), stage (seed/Series A) and therapeutic focus (biotech, medtech).

Broad incumbents

• Sofinnova Partners: One of Europe's largest life sciences VC platforms, with multiple strategies including early-stage biotech. Active co-investor alongside Invivo in Signadori Bio and a broader benchmark for European biotech VC.
• INKEF Capital: Dutch early-stage tech and healthtech investor. Comparable as a European early-stage VC with life sciences exposure; former employer of Invivo Senior Associate Marcos Casado.

Regional players

• NCL Technology Ventures: Israel/Europe-focused deeptech and life sciences VC. Comparable in early-stage biotech and AI-driven science exposure; provides a benchmark outside Spain for cross-border deal patterns.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invivo Capital Partners